NUVLAppointments•prnewswire•
Nuvalent Appoints Christy Oliger to Board of Directors
Sentiment:Neutral (50)
Summary
CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 18, 2025 by prnewswire